Palivizumab
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Palivizumab: From Respiratory Syncytial Virus Infection to Benign Neoplasm of Tongue
One-Sentence Summary
Palivizumab is a monoclonal antibody originally used against respiratory syncytial virus (RSV) infection. The TxGNN model predicts it may be effective for benign neoplasm of tongue, but no clinical trials and no publications currently support this direction. The prediction is based on the model score alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Respiratory syncytial virus infection (the Singapore licence text carries no indication wording; this is taken from the knowledge-graph indication record) |
| Predicted New Indication | Benign neoplasm of tongue |
| TxGNN Prediction Score | 99.94% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the data compiled for this report. Based on known information, palivizumab is a humanized monoclonal antibody directed against the RSV F protein, and its established use is in preventing RSV disease.
No plausible mechanistic link to benign tongue neoplasms has been identified. These tumours have no known RSV-related target, so the high score (99.94%) reflects a graph-based computational prediction only. Other highly ranked predictions for this drug (for example epiglottis neoplasm, cervical neuroblastoma, benign neoplasm of the hypopharynx, benign neoplasm of the floor of mouth, testicular and paratesticular tumours, schwannoma of the jugular foramen, and thyroglossal duct cyst) show the same pattern: all are L5, with no trials, no literature and no mechanistic rationale. This suggests the scores may reflect a general model pattern rather than drug-specific biology.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN15112P | SYNAGIS SOLUTION FOR INJECTION 100MG/ML (Boehringer Ingelheim Pharma GmbH & Co. KG) | Injection, solution | Not stated in the licence data |
Safety Considerations
Please refer to the package insert for safety information. No drug interaction records were found for palivizumab in the data compiled for this report.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by a model score, with no clinical trials, no literature and no plausible mechanistic link between an anti-RSV F protein antibody and benign tongue neoplasms. Package insert safety information has also not yet been obtained.
To proceed, the following is needed:
- Mechanism of action data (e.g., from DrugBank) and a documented biological rationale linking the RSV F protein target to the predicted disease
- Package insert warnings and contraindications from the HSA website, needed for safety screening
- Any preclinical or clinical evidence supporting palivizumab in this or related neoplastic conditions
- Confirmation of the approved indication wording for SIN15112P
- Assessment of route compatibility (the licensed form is injectable) and similarity to the original indication
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.